Skip to main content

COVID-19: Rapid identification of drugs to treat COVID-19 pneumonia


EMSL Project ID
51503

Abstract

Our proposal establishes that the angiotensin type 2 receptor (AT2R) as a potential therapeutic target for COVID-19 pneumonia. There is a growing body of evidence that activation of AT2R reduces lung injury in acute respiratory distress syndrome, a major cause of morbidity and mortality in COVID-19 infections. We propose approaches for rapidly identifying existing drugs that activate this receptor, as well as a more comprehensive strategy for longer term studies of AT2R that will lead to novel drug development. In our structure-based approach, iterative structure determination is necessary to facilitate the optimization of drug compounds. Cryo-EM has proven itself to be a powerful and indispensable tool for the consistent determination of membrane protein complex structures, and we will utilize cryo-EM as our primary structure determination method, thus the need to access Krios. All results will be made available to public through immediate publication on bioRxiv.

Project Details

Start Date
2020-07-05
End Date
2021-03-17
Status
Closed

Team

Principal Investigator

Bingfa Sun
Institution
ConfometRx, Inc.

Team Members

Dan Feng
Institution
ConfometRx, Inc.